Intimation for Appointment of Secretarial Auditor.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Ishita Drugs & Industries, at its meeting on May 30, 2025, approved the audited financial results for Q4 and full year ended March 31, 2025, along with the Directors' Report, Corporate Governance report, MD&A, and notice for the 32nd Annual General Meeting. The statutory auditor issued an unmodified (clean) opinion on the standalone annual results. Total assets grew to Rs. 1,629.58 lakhs from Rs. 1,080.87 lakhs year-on-year, while profit before tax rose to Rs. 115.51 lakhs from Rs. 98.73 lakhs. The board appointed M/s Meenu Maheshwari & Associates, a peer-reviewed practicing company secretary, as Secretarial Auditor for a five-year term, subject to shareholder approval. Internal auditors for FY 2025-26 were also re-appointed.
A clean audit opinion and steady profit growth are mildly positive signals for shareholders, suggesting financial credibility. However, operating cash flow turned sharply negative at Rs. -363.71 lakhs versus +Rs. 212.08 lakhs last year, which warrants attention despite stable year-end cash balances.